- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 527 Pages
Global
From €3640EUR$4,000USD£3,121GBP
- Report
- November 2021
- 802 Pages
Global
From €4551EUR$5,000USD£3,901GBP
- Report
- November 2021
- 1184 Pages
Global
From €5461EUR$6,000USD£4,681GBP
- Report
- November 2021
- 1165 Pages
Global
From €5461EUR$6,000USD£4,681GBP
- Report
- May 2023
- 216 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Report
- May 2023
- 274 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Report
- February 2023
- 427 Pages
Global
From €3249EUR$3,570USD£2,785GBP
- Report
- June 2022
- 297 Pages
Global
From €3145EUR$3,456USD£2,696GBP
- Report
- April 2022
- 262 Pages
Global
From €3145EUR$3,456USD£2,696GBP
- Book
- April 2018
- 200 Pages
- Book
- January 2023
- 560 Pages
- Book
- September 2024
- 304 Pages
- Book
- November 2023
- 304 Pages
- Book
- August 2022
- 304 Pages
- Book
- April 2022
- 352 Pages
- Book
- March 2022
- 896 Pages
- Book
- February 2021
- 416 Pages
The CRISPR market is a subset of the genomics market that focuses on the use of CRISPR-Cas9 technology for gene editing. CRISPR-Cas9 is a powerful tool that enables scientists to make precise changes to the genome of living organisms. This technology has been used to develop treatments for a variety of diseases, as well as to create new crops and livestock. CRISPR-Cas9 technology has also been used to create gene drives, which are designed to spread a desired trait through a population.
The CRISPR market is highly competitive, with a number of companies offering products and services related to gene editing. These companies include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, Caribou Biosciences, and ERS Genomics. These companies are developing a range of products, from gene editing tools to gene therapies, and are working to make CRISPR-Cas9 technology more accessible and affordable. Show Less Read more
